Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).

被引：0

作者：

Nauseef, Jones T. ^{[1
]}

Christos, Paul J. ^{[2
]}

Thomas, Charlene ^{[3
]}

Nordquist, Luke T. ^{[4
]}

Sternberg, Cora N. ^{[5
]}

Beltran, Himisha ^{[6
]}

Guervil, Sabrina ^{[7
]}

Galletti, Giuseppe ^{[8
]}

Giannakakou, Paraskevi ^{[8
]}

Nanus, David M. ^{[9
]}

Tagawa, Scott T. ^{[10
]}

Molina, Ana M. ^{[3
]}

机构：

[1] Weill Cornell Med Ctr, NewYork Presbyterian Hosp, New York, NY USA

[2] Weill Cornell Med Coll, Dept Biostat & Epidemiol, New York, NY USA

[3] Weill Cornell Med, New York, NY USA

[4] GU Res Network, Omaha, NE USA

[5] Weill Cornell Med, Englander Inst Precis Med, New York, NY USA

[6] Dana Farber Canc Inst, Boston, MA 02115 USA

[7] Weill Cornell Med Ctr, New York, NY USA

[8] Meyer Canc Ctr, Weill Cornell Med, New York, NY USA

[9] Sandra & Edward Meyer Canc Ctr, New York, NY USA

[10] Weill Cornell Med Coll, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期

关键词：

D O I：

10.1200/JCO.2021.39.6_suppl.140

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

140

引用

页数：2

共 50 条

[1] Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
Molina, Ana
Christos, Paul
Hackett, Amy
Nordquist, Luke
Gelmann, Edward
Stein, Mark
Sternberg, Cora
Beltran, Himisha
Gracey, Lauren
Galletti, Giuseppe
Giannakakou, Paraskevi
Nanus, David M.
Tagawa, Scott T.
CANCER RESEARCH, 2019, 79 (13)
[2] Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy.
Posadas, Edwin M.
Chi, Kim N.
De Wit, Ronald
De Jonge, Maja J.
Attard, Gerhardt
Friedlander, Terence W.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
[3] Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
Massard, C.
Mateo, J.
Loriot, Y.
Pezaro, C.
Albiges, L.
Mehra, N.
Varga, A.
Bianchini, D.
Ryan, C. J.
Petrylak, D. P.
Attard, G.
Shen, L.
Fizazi, K.
de Bono, J.
ANNALS OF ONCOLOGY, 2017, 28 (01) : 90 - 95
[4] Overall survival from PANTHER: A multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC).
George, Daniel J.
Halabi, Susan
Fleming, Mark T.
Heath, Elisabeth I.
Tutrone, Ronald
Sutton, Linda
Whang, Young E.
Lewis, Brian E.
Humeniuk, Michael Sandon
Harrison, Michael Roger
Kephart, Julie
Hurrelbrink, Julia
Rasmussen, Julia
Shobe, Kellie
Anand, Monika
Reyes-Martinez, Marco
Howard, Lauren
Patierno, Steven R.
Freedman, Jennifer A.
Armstrong, Andrew J.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] Predictors of outcome to post-docetaxel abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (p)
Ochoa de Olza, M.
Font, A.
Sala, N.
Beltran, M.
Barretina, P.
Etxaniz, O.
Indacoechea, A.
Hernandez, A.
Navarro, V.
Germa, J. R.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S701 - S701
[6] Health-related quality of life (HRQoL) in ACIS: A phase III trial of apalutamide with abiraterone acetate and prednisone (APA plus AAP) vs AAP in metastatic castration-resistant prostate cancer (mCRPC)
Oudard, S. M.
Bevans, K. B.
Attard, G.
Efstathiou, E.
Flaig, T. W.
Franke, F. A.
Goodman, O. B., Jr.
De Giorgi, U.
Pieczonka, C. M.
Yeruva, K.
De Porre, P.
Brookman-May, S. D.
Dibaj, S.
Wu, D.
Mundle, S. D.
McCarthy, S.
Steuber, T.
Suzuki, H.
Rathkopf, D. E.
Saad, F.
ANNALS OF ONCOLOGY, 2021, 32 : S634 - S634
[7] A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
Climent, Miguel A.
Font, Albert
Duran, Ignacio
Puente, Javier
Mendez-Vidal, Maria Jose
Isabel Saez, Maria
Lobera, Carmen Santander
Arranz Arija, Jose Angel
Gonzalez-Del-Alba, Aranzazu
Sanchez-Hernandez, Alfredo
Juan Fita, Maria Jose
Esteban, Emilio
Alonso-Gordoa, Teresa
Mellado Gonzalez, Begona
Maroto, Pablo
Lazaro-Quintela, Martin
Cassinello-Espinosa, Javier
Perez-Valderrama, Begona
Garcias, Carmen
Castellano, Daniel
EUROPEAN JOURNAL OF CANCER, 2022, 175 : 110 - 119
[8] Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer
Tagawa, Scott T.
Posadas, Edwin M.
Bruce, Justine
Lim, Emerson A.
Petrylak, Daniel P.
Peng, Weimin
Kheoh, Thian
Maul, Scott
Smit, Johan W.
Gonzalez, Martha D.
De Porre, Peter
NamPhuong Tran
Nanus, David M.
EUROPEAN UROLOGY, 2016, 70 (05) : 718 - 721
[9] Phase I study of apalutamide (ARN) plus abiraterone acetate (AA), docetaxel (D) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
Molina, A. M.
Christos, P. J.
Whang, Y.
Nordquist, L.
Hackett, A. L.
Beltran, H.
Faltas, B.
Nanus, D.
Giannakakou, P.
Tagawa, S. T.
ANNALS OF ONCOLOGY, 2017, 28
[10] Evaluation of continuous abiraterone acetate (AA) plus prednisone (P) dosing in fasting and fed states in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Chi, K. N.
Spratlin, J.
Kollmannsberger, C.
North, S.
Pankras, C.
Chien, C.
Gonzalez, M.
Pang, L.
Yu, M. K.
Tran, N. P.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S696 - S697

← 1 2 3 4 5 →